Dan Renick Featured in Pharmaceutical Commerce
Precision for Value president Dan Renick is interviewed for Pharmaceutical Commerce, providing his in-depth perspective on today’s payer and provider markets.
Making the Case for Evidence Synthesis in Clinical Leader
In a new article for Clinical Leader, PHE’s Ross Maclean and Jeroen Jansen explain how evidence synthesis can reduce the guesswork of clinical trial design.
Pricing and Contracting Strategy for a Biosimilar Launch
A large manufacturer client was preparing to launch a biosimilar into a highly competitive and complex market. In this case study, the brand team sought to learn how payers would view the product in relation to key competitors, understand decision drivers and thresholds, and identify potential competitive reactions resulting from any actions taken.
Integrating Existing Data to Capture a Complete Picture of Payer Behavior
Learn how one pharmaceutical manufacturer overcame inconsistencies in tracking payer coverage and performance across the organization. With the application of a Payer Plan Hierarchy, the client was able to better understand the payer landscape and had a more direct and consistent line of sight on supporting product performance in managed markets contexts.
Download the New Oncology Research Brief from Precision Health Economics
How is value defined in cancer care? What do patients value most?
As healthcare spending continues to rise, payers and providers struggle to accurately measure value to patients, and with health systems all over the world shifting towards paying for value, not just volume, these efforts have never been more important.
Jeremy Schafer Addresses Sanofi/Regeneron’s dupilumab in BioPharm Insight
Precision for Value’s Jeremy Schafer comments on pricing and reimbursement of dupilumab, Sanofi/Regeneron’s first atopic dermatitis biologic, in BioPharm Insight.
Precision for Value’s Hepatitis C Survey Discussed in Managed Healthcare Executive: Here’s What’s Missing
Precision for Value’s Jeremy Schafer highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Schafer Discusses Hepatitis C Drug Safety Concerns in Drug Topics
Precision for Value’s Jeremy Schafer discusses safety concerns over some hepatitis C drugs in the latest edition of Drug Topics.
Commentary: Why Value-Based Pricing’s Time Has Come, and It’s Here to Stay
PHE economist Jason Shafrin talks prices, politics, and the problem of monopolies with eyeforpharma’s Hugh Gosling.
Press Release: NCQA’s HEDIS® Data Now Incorporated Into Precision for Value’s Qnav® Tool
Life Sciences Companies Now Given Unprecedented Access and Visualization of Quality Performance Data
JOINT PRESS RELEASE
February 8, 2017 – New York, NY – Life sciences companies stand to be the primary beneficiary of a unique license agreement that integrates the industry’s most robust quality performance data available into a single tool. Precision for Value (PFV) has entered into an arrangement with the National Committee for Quality Assurance (NCQA) to incorporate the Healthcare Effectiveness Data and Information Set (HEDIS®) data into the PFV Quality Navigator Tool (Qnav®).